«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2012年第5期

页码:

625-629，633

栏目:

临床研究

出版日期:

2012-10-25

文章信息/Info

Title:

Meta-analysis of randomized controlled trials of intracoronary vs. intravenous administration of abciximab during percutaneous coronary intervention for ST-elevation myocardial infarction

作者:

刘林琼¹; 耿召华²

(1.重庆市巴南区人民医院心内科，重庆 401320；
2.第三军医大学附属新桥医院心内科，重庆 400037)

Author(s):

LIU Lin-qiong¹;  GENG Zhao-hua²

(1.Department of Cardiology, People’s Hospital of Banan District, Chongqing 401320, China; 2.Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China) )

关键词:

阿昔单抗;  心肌梗死; ST段抬高型; 急性; 冠状动脉内注射; 静脉注射

Keywords:

abciximab;  ST-elevation myocardial infarction;  intracoronary;  intravenous

分类号:

R541.4

DOI:

-

文献标识码:

A

摘要:

目的:比较冠状动脉介入治疗（PCI）中冠状动脉内和静脉内使用阿昔单抗的治疗效果。方法： 计算机检索 PubMed、 EMbase、 Cochrane图书馆、 中国生物医学文献光盘数据等数据库，系统性搜索已发表的相关临床研究，并对纳入的研究进行质量评价，对相关结果进行meta分析。共纳入6个随机对照临床研究，共1 138例患者，其中试验组580例（冠状动脉内运用阿昔单抗组），对照组558 例（静脉内运用阿昔单抗组）。纳入患者均为急性ST段抬高型心肌梗死。结果： 冠状动脉内运用阿昔单抗组仅在心肌梗死溶栓后Ⅲ级血流所占比例优于静脉内运用阿昔单抗组［RR=1.06，95%CI（1.01，1.12），P=0.02］。而在病死率［RR=0.48，95%CI（0.23，1.02），P=0.06］、靶血管血运重建［RR=0.55，95%CI（0.30，0.99），P=0.05］，以及出血事件发生率［RR=0.88，95%CI（0.63，1.23），P=0.44］，两组没有统计学意义上的差异。结论：与静脉内使用阿昔单抗组相比，冠状动脉内使用阿昔单抗改善了急性ST段抬高型心肌梗死患者的心肌灌注，但并未降低其病死率、靶血管血运重建及出血事件发生率。

Abstract:

AIM:To compare the effect of intracoronary (IC) vs. intravenous (IV) administration of abciximab during percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). METHODS: Published research was retrieved mainly from electronic databases (PubMed, EMBASE and the Cochrane Central Register of Controlled Trials). All randomized controlled trials comparing IC and IV administration of abciximab were included. RESULTS: A total of six randomized trials were included in the current meta-analysis, involving 1 138 patients. IC administration was more effective than IV administration of abciximab only in patients with thrombolysis in MI grade III flow ［RR=1.06, 95% CI(1.01, 1.12), P=0.02］. No statistically significant difference was found between the IC and IV groups according to the mortality rate ［RR=0.48, 95% CI(0.23, 1.02), P=0.06］, target vessel revascularization ［RR=0.55, 95% CI(0.30, 0.99), P=0.05］ and bleeding events ［RR=0.88, 95% CI(0.63, 1.23), P=0.44］. CONCLUSION: Compared with IV administration of abciximab, IC administration of abciximab improves myocardial reperfusion but does not reduce mortality rate, target vessel revascularization, or bleeding events in STEMI patients undergoing primary PCI.

参考文献/References

[1]Davies MJ,Thomas A.Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death[J].N Engl J Med,1984,310(18):1137-1140.
[2]Antman EM,Hand M,Armstrong PW,et al.2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian cardiovascular society endorsed by the American Academy of Family Physicians: 2007 writing group to review new Evidence and Update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial Infarction, writing on behalf of the 2004 writing committee[J].Circulation,2008,117(2):296-329.
[3]Keeley EC,Boura JA,Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials[J].Lancet,2003, 361(1):13-20.
[4]Lerman A,Holmes DR,Herrmann J,et al.Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence,or both?[J].Eur Heart J,2007,28(7):788-797.
[5]Sezer M,Oflaz H,Goren T,et al.Intracoronary streptokinase after primary percutaneous coronary intervention[J].N Engl J Med,2007,356(18):1823-1834.
[6]Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.The EPIC Investigation[J].N Engl J Med,1994,330(14):956-961.
[7]Topol EJ,Califf RM,Weisman HF,et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis:results at six months. The EPIC Investigators[J].Lancet,1994,343(8902):881-886.
[8]Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators[J].N Engl J Med,1997,336(24):1689-1696.
[9]Topol EJ,Mark DB,Lincoff AM,et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial.EPISTENT Investigators.Evaluation of Platelet IIb/IIIa Inhibitor for Stenting[J].Lancet,1999,354(9195):2019-2024.
[10]Ndrepepa G,Kastrati A,Mehilli J,et al.One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial[J].Eur Heart J,2008,29(4):455-461.
[11]Bellandi F,Maioli M,Gallopin M,et al.Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention[J].Catheter Cardiovasc Interv,2004,62(2):186-192.
[12]Dominguez-Rodriguez A,Abreu-Gonzalez P,Avanzas P,et al.Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations[J].Atherosclerosis, 2009,206(2):523-527.
[13]Eitel I,Friedenberger J, Fuernau G,et al.Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention:6-month effects on infarct size and left ventricular function.The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI)[J].Clin Res Cardiol,2011,100(5):425-432.
[14]Gu YL,Kampinga MA,Wieringa WG,et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial［J］. Circulation, 2010, 122(25):2709-2717.
[15]Iversen A, Abildgaard U, Galloe A, et al. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial［J］. J Interv Cardiol, 2011, 24(2):105-111.
[16]Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial［J］. Circulation, 2008, 118(1):49-57.
[17]Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial[J].Circulation,2010,121(6):784-791.
[18]Sharma S,Makkar R, Lardizabal J.Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?[J].J Cardiovasc Pharmacol Ther,2006,11(2):136-141.

备注/Memo

备注/Memo:

收稿日期：2012-03-22.
通讯作者：耿召华，副教授，主要从事心力衰竭病理机制研究Email:gengzhh@tom.com
作者简介：刘林琼，主治医师Email:Guaiguaimamao@163.com

常用功能

更新日期/Last Update: 2012-11-16